News
Wegovy, FDA and Novo Nordisk
Digest more
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
Investor's Business Daily on MSN5h
Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.
Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH.
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a new indication for Wegovy® ...
The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...
The FDA has granted accelerated approval to semaglutide (Wegovy; Novo Nordisk) injection 2.4 mg for the treatment of adults with metabolic dysfunction–associated steatohepatitis (MASH) with moderate ...
Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback